Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Gliosarcoma 5Glioblastoma 5Brain Neoplasms 4Oligodendroglioma 3Astrocytoma 3Prostatic Neoplasms 2Optic Nerve Glioma 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1

Interventions

Cytarabine 26Etoposide 14Daunorubicin 11tipifarnib 10Mitoxantrone 10Idarubicin 7alvocidib 6Azacitidine 6Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Busulfan 5valspodar 4Vorinostat 4fludarabine phosphate 3aldesleukin 3Tretinoin 3Sorafenib 3Radiotherapy 3Gemtuzumab 3Cyclophosphamide 3Bortezomib 3tanespimycin 2sargramostim 2lintuzumab 2laromustine 2entinostat 2Watchful Waiting 2Topotecan 2Thioguanine 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Erythroblastic, Acute × Cilengitide × Clear all
NCT00089388 2013-01-24

Cilengitide in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
70 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡